Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592371 · ClinicalTrials.gov registry record
Head and Neck Cancer Screening and Serum Repository
A clinical trial of Head and Neck Squamous Cell Cancer, sponsored by University of Arkansas.
- Completed
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT00592371 is a study of Head and Neck Squamous Cell Cancer that has completed, run by University of Arkansas. The registered enrollment target is 300 participants, above the 216-participant average among 4 other Head and Neck Squamous Cell Cancer trials with a reported enrollment target (39% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00592371, a study of Head and Neck Squamous Cell Cancer, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Head and Neck Squaumous Cell Cancer(HNSCC) is the 6th most common cancer in the United States and the 3rd most common worldwide. Risk factors include abuse to tobacco and alcohol. Survival is related to stage of HNSCC when treatment is sought. Most HNSCC patients present with advanced staged disease. This screening activity will educate patients with HNSCC rick factors and screen for pre malignant and/or early staged lesions.
Conditions Studied
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592371
The ClinicalTrials.gov registry entry for NCT00592371 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 216-participant average among 4 other Head and Neck Squamous Cell Cancer trials with a reported enrollment target (39% higher). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Squamous Cell Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00592371 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT00592371 about?
NCT00592371 is a clinical study titled "Head and Neck Cancer Screening and Serum Repository". Head and Neck Squaumous Cell Cancer(HNSCC) is the 6th most common cancer in the United States and the 3rd most common worldwide. Risk factors include abuse to tobacco and alcohol. Survival is related to stage of HNSCC when treatment is sought. Most HNSCC patients present with advanced staged disease...
What is the current status of trial NCT00592371?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2006-03. Estimated completion is 2012-09.
What conditions does trial NCT00592371 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Cancer.
Who is sponsoring clinical trial NCT00592371?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00592371 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RECRUITING · Phase 1
-
Study of XB010 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.